The human brain comprises billions of neurons, synapses, and cell types, making it one of the universe's most intricate and ...

Neurodegenerative diseases like Parkinson’s and Alzheimer’s affect millions of people and are becoming more common as the ...

The endorsement means the EMA will offer Carthera support and advice as it moves towards a regulatory filing for its ...

DelveInsight's Traumatic Brain Injury pipeline report depicts a robust space with 20+ active players working to develop 22+ ...

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

Brain swelling, or cerebral edema, is a medical emergency. Learn about the evidence-based treatments doctors use to reduce ...

Discover 5 dangerous drug-resistant fungi posing epidemic threats. Learn how these deadly superbugs are spreading and what ...

A cancer immunotherapy may slow Parkinson’s disease by blocking the spread of harmful brain proteins, Johns Hopkins researchers found.

Following positive opinion, Carthera is one of the first companies to benefit from brand-new status – intended to support early access pathways for innovative devices targeting rare diseasesParis, ...

Roche has been attempting to develop an Alzheimer's drug for some time, and its first attempts with two other anti-amyloid antibodies – crenezumab and gantenerumab – ended in failure.

Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered ...

Studies demonstrate that L-Theanine can improve attention and reduce mental fatigue without causing sedation. When combined ...